Menu Close

Mark Blaskovich


Mark tweets at @Mark_Blaskovich

Dr. Mark Blaskovich is an Professor and Director of Translation at the Institute for Molecular Bioscience at The University of Queensland.

He has extensive medicinal chemistry expertise resulting from more than 16 years of industrial drug development experience.

As Chief Operating Officer at Mimetica (Australia), he managed the drug discovery and development program for melanocortin-5 receptor antagonists, leading to a compound currently in Phase II human trials.

In his previous role at CEPTYR (Seattle) he led a multidisciplinary team that developed a preclinical candidate that inhibited protein tyrosine phosphatase 1B for the treatment of diabetes, while at Molecumetics (Seattle) he headed a $2m/yr industrial collaboration on peptidomimetic compounds targeting proteases and GPCRs.

Mark is currently developing new antibiotics to treat drug resistant pathogens and new methods to diagnose infections.

He has published more than 140 articles, is an inventor on 11 families of patents, and is author of 'The Handbook on Syntheses of Amino Acids'.


  • 2010–present
    Senior Research Officer, Institute for Molecular Bioscience, University of Queensland
  • 2005–2009
    Chief Operating Officer, Mimetica
  • 2002–2005
    Associate Director of Chemistry, CEPTYR
  • 1997–2002
    Group Leader, Molecumetics


  • 1993 
    University of Waterloo, Ph.D. Organic Chemistry
  • 1987 
    University of Victoria, B.Sc. Chemistry Co-op Honours


  • 2011
    Handbook on Synthesis of Amino Acids, Oxford University Press

Research Areas

  • Organic Chemistry (0305)
  • Medicinal And Biomolecular Chemistry (0304)
  • Organic Chemical Synthesis (030503)
  • Molecular Medicine (030405)
  • Medical Microbiology (1108)
  • Medical Bacteriology (110801)
  • Microbiology (0605)